BREAKING NEWS: GTBP!
GT Biopharma Inc. (OTCQB: GTBP) announced today that it has initiated the Proof of Concept Phase I clinical trial with GTP-004, a novel treatment for the symptoms of myasthenia gravis, a rare autoimmune muscular disease caused by antibodies that attack certain components of muscles leading to varying degrees of weakness and fatigue. The prevalence of myasthenia gravis in the United States is estimated at 14 to 20 per 100,000 population, approximately 36,000 to 60,000 cases in the U.S. (Howard, 2015).
Cellectis Appoints Well-Known Cancer R&D Chief
Stéphane Depil, M.D., Ph.D. has been appointed Cellectis’ CMO and senior vice president of Research and Development. This marks Depil’s, former director of oncology R&D at Servier, homecoming to the industry after directing the cancer immunotherapy program at a cancer center. Depil shall continue as an adjunct professor in academic and research activities at the Léon Bérard Cancer Center in Lyon.
BIOTECHSTOCKS,.com is owned by MIDAM VENTURES LLC., a Florida Corporation that has been compensated $950,000.00 by a GT Biopharma Inc. for a period beginning August 1, 2017 and ending Nov. 1, 2017 now extended to December 31, 2018 to publicly disseminate information about (GTBP). We own zero shares.